Your browser doesn't support javascript.
loading
Using the Plasma Proteome for Risk Stratifying Patients with Pulmonary Arterial Hypertension.
Rhodes, Christopher J; Wharton, John; Swietlik, Emilia M; Harbaum, Lars; Girerd, Barbara; Coghlan, J Gerry; Lordan, James; Church, Colin; Pepke-Zaba, Joanna; Toshner, Mark; Wort, Stephen J; Kiely, David G; Condliffe, Robin; Lawrie, Allan; Gräf, Stefan; Montani, David; Boucly, Athénaïs; Sitbon, Olivier; Humbert, Marc; Howard, Luke S; Morrell, Nicholas W; Wilkins, Martin R.
  • Rhodes CJ; National Heart and Lung Institute, Imperial College London, London, United Kingdom.
  • Wharton J; National Heart and Lung Institute, Imperial College London, London, United Kingdom.
  • Swietlik EM; Department of Medicine, University of Cambridge, Cambridge, United Kingdom.
  • Harbaum L; National Heart and Lung Institute, Imperial College London, London, United Kingdom.
  • Girerd B; Université Paris-Saclay, AP-HP, INSERM UMR_S 999, Department of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Centre, Hôpital de Bicêtre, Le Kremlin Bicêtre, France.
  • Coghlan JG; Department of Cardiology, Royal Free Campus, University College London, London, United Kingdom.
  • Lordan J; University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom.
  • Church C; University of Glasgow, Glasgow, Scotland, United Kingdom.
  • Pepke-Zaba J; Pulmonary Vascular Disease Unit, Royal Papworth Hospital, Cambridge, United Kingdom.
  • Toshner M; Department of Medicine, University of Cambridge, Cambridge, United Kingdom.
  • Wort SJ; National Heart and Lung Institute, Imperial College London, London, United Kingdom.
  • Kiely DG; Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom.
  • Condliffe R; Sheffield Pulmonary Vascular Unit, Royal Hallamshire Hospital, Sheffield, United Kingdom; and.
  • Lawrie A; Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom.
  • Gräf S; Sheffield Pulmonary Vascular Unit, Royal Hallamshire Hospital, Sheffield, United Kingdom; and.
  • Montani D; Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom.
  • Boucly A; Department of Medicine, University of Cambridge, Cambridge, United Kingdom.
  • Sitbon O; BioResource for Translational Research, National Institute for Health Research Cambridge Biomedical Campus, Cambridge, United Kingdom.
  • Humbert M; Université Paris-Saclay, AP-HP, INSERM UMR_S 999, Department of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Centre, Hôpital de Bicêtre, Le Kremlin Bicêtre, France.
  • Howard LS; Université Paris-Saclay, AP-HP, INSERM UMR_S 999, Department of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Centre, Hôpital de Bicêtre, Le Kremlin Bicêtre, France.
  • Morrell NW; Université Paris-Saclay, AP-HP, INSERM UMR_S 999, Department of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Centre, Hôpital de Bicêtre, Le Kremlin Bicêtre, France.
  • Wilkins MR; Université Paris-Saclay, AP-HP, INSERM UMR_S 999, Department of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Centre, Hôpital de Bicêtre, Le Kremlin Bicêtre, France.
Am J Respir Crit Care Med ; 205(9): 1102-1111, 2022 05 01.
Article en En | MEDLINE | ID: mdl-35081018

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Hipertensión Arterial Pulmonar Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Hipertensión Arterial Pulmonar Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article